Patents by Inventor Kevin CROSSLEY

Kevin CROSSLEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230099078
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.
    Type: Application
    Filed: June 28, 2022
    Publication date: March 30, 2023
    Inventors: Jeroen BEZEMER, Ying CHEN, Richard CROCKETT, Kevin CROSSLEY, Sheng CUI, Liang HUANG, Sian JONES, Asher LOWER, Krishnakumar RANGANATHAN
  • Patent number: 11377474
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: July 5, 2022
    Assignee: AMGEN INC.
    Inventors: Jeroen Bezemer, Ying Chen, Richard Crockett, Kevin Crossley, Sheng Cui, Liang Huang, Sian Jones, Asher Lower, Krishnakumar Ranganathan
  • Patent number: 10858389
    Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: December 8, 2020
    Assignee: Amgen Inc.
    Inventors: Sheng Cui, Krishnakumar Ranganathan, Richard Crockett, Ying Chen, Aleksander Swietlow, Kevin Crossley, Yun Shi, Karel Decroos, Etienne Moniotte
  • Publication number: 20190352336
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 21, 2019
    Inventors: Jeroen BEZEMER, Ying CHEN, Richard CROCKETT, Kevin CROSSLEY, Sheng CUI, Liang HUANG, Sian JONES, Asher LOWER, Krishnakumar RANGANATHAN
  • Patent number: 10407464
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: September 10, 2019
    Assignee: Amgen Inc.
    Inventors: Jeroen Bezemer, Ying Chen, Richard Crockett, Kevin Crossley, Sheng Cui, Liang Huang, Sian Jones, Asher Lower, Krishnakumar Ranganathan
  • Publication number: 20180079777
    Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.
    Type: Application
    Filed: March 25, 2016
    Publication date: March 22, 2018
    Inventors: Sheng Cui, Krishnakumar Ranganathan, Richard Crockett, Ying Chen, Aleksander Swietlow, Kevin Crossley, Yun Shi, Karel Decroos, Etienne Moniotte
  • Publication number: 20170190739
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease—mineral and bone disorder (CKD-MBD).
    Type: Application
    Filed: April 3, 2015
    Publication date: July 6, 2017
    Inventors: Jeroen BEZEMER, Ying CHEN, Richard CROCKETT, Kevin CROSSLEY, Sheng CUI, Liang HUANG, Sian JONES, Asher LOWER, Krishnakumar RANGANATHAN